PrintThe Burrill Report
The Burrill Report (January 14, 2013): California's Biomedical Industry Shows Resiliance (.MP3,15.77 Mb)
California’s biomedical industry has shown resilience through the deep recession of recent years, according to a new report from BayBio, the California Healthcare Institute, and PwC. The state’s biomedical industry has grown at an average annual rate of 0.5 percent over the past five years and the state leads the nation in producing new treatments, capturing venture investment, and NIH research dollars. We spoke to Gail Maderis, president and CEO of BayBio, about the report, the challenges that life sciences companies face today, and what the changing landscape for both investment and reimbursement means to companies in California and elsewhere.
January 11, 2013
http://www.burrillreport.com/article-californias_biomedical_industry_shows_resilience.html
ECONOMIC DEVELOPMENT
California's Biomedical Industry Shows Resilience
Podcast: January 14, 2013[Please login to post comments]
- Just What the Doctor Ordered
January 21, 2013 Read More - Optum Labs Research Center Open for Business
UnitedHealth Group and Mayo Clinic form an open, collaborative research and development program. Read More - AstraZeneca and Vanderbilt Collaborate on Brain Disorders
Partnership opens new front in company’s effort to develop promising external neuroscience research. Read More - Generic HIV Treatment Could Save $1 Billion Annually
Despite cutting costs, generics switch may leave patients with less effective treatments. Read More - Boosting Venture Capital in Canada
Government plans to deploy $400 million toward the creation of large-scale VC funds led by private sector. Read More - Big Pharma’s Reputation Sinks with Patient Groups
Annual survey finds a big drop in scores from advocates. Read More - U.S. Public Biotechs Raise $1.2 Billion in Equity and Debt
Improved outlook for biotech spurs opportunity to raise money. Read More - Court Ruling Creates Liability for Branded Drugmakers
Alabama Supreme Court finds innovator can be sued for disclosures relating to competitors products. Read More - FDA Green-lights Neuralstem Trial
Early-stage study will use company’s lead cell therapy in patients with chronic spinal cord injury. Read More - BMS Moves to Wrap Up Litigation Over Failed Trial
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More
.gif)
